MP
CUE icon

Mangrove Partners’s Cue Biopharma CUE Stock Holding History

Mangrove Partners’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-20,047
Closed -$8.53M – 58
2020
Q1 		$8.53M Hold
20,047
– – 1.18% 23
2019
Q4 		$9.55M Buy
+20,047
New +$6.3M 1.4% 21

Other funds holding CUE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Mangrove Partners's CUE Position: Q2 2020 in Review

Mangrove Partners sold out of Cue Biopharma (CUE) in Q2 2020, closing a stake of 20,047 shares — an estimated $8.53M sold.

Mangrove Partners first reported a position in CUE in Q4 2019 and held it in 2 quarters. The position peaked at $9.55M in Q4 2019. 99 funds tracked by Wall St. Rank hold CUE as of Q2 2020.

  • Mangrove Partners reported no remaining Cue Biopharma position as of Q2 2020 after selling out during the quarter.
  • Mangrove Partners sold 20,047 Cue Biopharma shares in Q2 2020, an estimated $8.53M.
  • Mangrove Partners first reported a position in Cue Biopharma in Q4 2019 and held it in 2 quarters.
  • Mangrove Partners's Cue Biopharma position peaked at $9.55M in Q4 2019.
  • 99 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2020.

Based on Mangrove Partners's 13F filing for Q2 2020, filed 14 Aug 2020.